![[Logo]FUJIFILM](/en/template/images/gHeader_brandLogo_02.gif){kind=small}
![[Logo]KYOWA KIRIN](/en/template/images/gHeader_brandLogo_01.gif){kind=small}
![[Logo]FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.](/en/template/images/gHeader_coName_01.gif){kind=small}
What's New
The information in news releases is current at the time of the release. Note that the information shown here may not be latest information and may be subject to change without prior notice.
What's New
- Oct. 19, 2016
- Fujifilm Kyowa Kirin Biologics Announces Positive Result in Primary Endpoint from Phase 3 Study of Adalimumab Biosimilar, anti-TNF- Monoclonal Antibody
- Jul. 24, 2015
- Fujifilm Kyowa Kirin Biologics establishes joint venture with AstraZeneca to develop and commercialise anti-VEGF biosimilar
- Oct. 10, 2013
- Europe Branch opened by Fujifilm Kyowa Kirin Biologics
- Feb. 26, 2013
- Production & Development Centre opened by Fujifilm Kyowa Kirin Biologics
- Oct. 24, 2012
- Fujifilm Kyowa Kirin Biologics to initiate development of biosimilar of bevacizumab, an anti-VEGF humanized monoclonal antibody which has impressive therapeutic effects for cancers such as colorectal cancer
- Mar. 27, 2012
- Establishment of Fujifilm Kyowa Kirin Biologics
- Nov. 16, 2011
- Fujifilm and Kyowa Hakko Kirin to set up a joint venture for the development of biosimilars